Sun Pharmaceutical Industries Ltd · SUNPHARMA · Pharma - Formulators · price as of the 12 November 2026 close, updated every trading day · results updated weekly · research updated 30 October 2026
Sun Pharma share price today: ₹1,885.00 at the close on 12 November 2026, up 7.3% in a year. Sun Pharmaceutical Industries (SUNPHARMA) is worth ₹4,52,274 crore, trades at a P/E of 41.2 and has closed between ₹1,610.10 and ₹1,990.50 over the past 52 weeks. Latest change: foreign funds (FIIs) cut their stake for 7 quarters in a row.
Sun Pharmaceutical Industries Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer.
The main question: domestic institutions moved +3.8 percentage points over 8 quarters while the business went the other way.
The price has been stalling near its high for 3 weeks, and the P/E is higher than 95% of its own last 11 years. Over the last four quarters, results have been deteriorating, with profit −36.2% on a year earlier, and 120% of the last 3 years' profit came in as cash. What will decide it: whether the owners’ moves turn back in line with the business.
What is the Sun Pharma share price today?
Sun Pharmaceutical Industries Ltd's share price was ₹1,885.00 at the close on 12 November 2026. It has been stalling near its high for 3 weeks. That is 3.9% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sun Pharmaceutical Industries Ltd is in stage 3. The phase helps read everything below.
In the last 52 weeks it traded between ₹1,610 and ₹1,991, and at that close it sat 72% of the way up from that low.
Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 278 of 550 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 11 Mar 2016 | no NIFTY 500 reading |
| 18 Mar 2016 | no NIFTY 500 reading |
| 23 Mar 2016 | no NIFTY 500 reading |
| 1 Apr 2016 | no NIFTY 500 reading |
| 8 Apr 2016 | no NIFTY 500 reading |
| 13 Apr 2016 | no NIFTY 500 reading |
| 22 Apr 2016 | no NIFTY 500 reading |
| 29 Apr 2016 | no NIFTY 500 reading |
| 6 May 2016 | no NIFTY 500 reading |
| 13 May 2016 | no NIFTY 500 reading |
| 20 May 2016 | no NIFTY 500 reading |
| 27 May 2016 | no NIFTY 500 reading |
| 3 Jun 2016 | no NIFTY 500 reading |
| 10 Jun 2016 | −24.6% |
| 17 Jun 2016 | −15.9% |
| 24 Jun 2016 | −18.1% |
| 1 Jul 2016 | −16.9% |
| 8 Jul 2016 | −13.4% |
| 15 Jul 2016 | −16.2% |
| 22 Jul 2016 | −13.3% |
| 29 Jul 2016 | −9.2% |
| 5 Aug 2016 | −5.7% |
| 12 Aug 2016 | −10.2% |
| 19 Aug 2016 | −12.4% |
| 26 Aug 2016 | −18.4% |
| 2 Sep 2016 | −4.1% |
| 9 Sep 2016 | −1.0% |
| 16 Sep 2016 | −3.6% |
| 23 Sep 2016 | −5.4% |
| 30 Sep 2016 | −10.0% |
| 7 Oct 2016 | −8.3% |
| 14 Oct 2016 | −7.2% |
| 21 Oct 2016 | −7.4% |
| 30 Oct 2016 | −10.1% |
| 4 Nov 2016 | −22.2% |
| 11 Nov 2016 | −8.4% |
| 18 Nov 2016 | −5.3% |
| 25 Nov 2016 | +0.0% |
| 2 Dec 2016 | +0.4% |
| 9 Dec 2016 | −9.6% |
| 16 Dec 2016 | −9.5% |
| 23 Dec 2016 | −11.2% |
| 30 Dec 2016 | −8.1% |
| 6 Jan 2017 | −10.5% |
| 13 Jan 2017 | −9.2% |
| 20 Jan 2017 | −13.4% |
| 27 Jan 2017 | −18.1% |
| 3 Feb 2017 | −5.7% |
| 10 Feb 2017 | −13.5% |
| 17 Feb 2017 | −14.1% |
| 23 Feb 2017 | −15.1% |
| 3 Mar 2017 | −15.3% |
| 10 Mar 2017 | −10.7% |
| 17 Mar 2017 | −4.3% |
| 24 Mar 2017 | −3.1% |
| 31 Mar 2017 | −5.9% |
| 7 Apr 2017 | −8.1% |
| 13 Apr 2017 | −4.3% |
| 21 Apr 2017 | −11.3% |
| 28 Apr 2017 | −9.2% |
| 5 May 2017 | −11.9% |
| 12 May 2017 | −11.5% |
| 19 May 2017 | −8.3% |
| 26 May 2017 | −23.5% |
| 2 Jun 2017 | −34.3% |
| 9 Jun 2017 | −30.4% |
| 16 Jun 2017 | −33.0% |
| 23 Jun 2017 | −27.0% |
| 30 Jun 2017 | −23.6% |
| 7 Jul 2017 | −23.8% |
| 14 Jul 2017 | −25.3% |
| 21 Jul 2017 | −16.2% |
| 28 Jul 2017 | −21.0% |
| 4 Aug 2017 | −23.5% |
| 11 Aug 2017 | −34.2% |
| 18 Aug 2017 | −33.9% |
| 24 Aug 2017 | −18.7% |
| 1 Sep 2017 | −9.1% |
| 8 Sep 2017 | −15.5% |
| 15 Sep 2017 | −6.8% |
| 22 Sep 2017 | −8.4% |
| 29 Sep 2017 | −12.5% |
| 6 Oct 2017 | −5.8% |
| 13 Oct 2017 | −10.3% |
| 19 Oct 2017 | −10.6% |
| 27 Oct 2017 | −5.3% |
| 3 Nov 2017 | +3.3% |
| 10 Nov 2017 | +13.4% |
| 17 Nov 2017 | +2.9% |
| 24 Nov 2017 | +7.1% |
| 1 Dec 2017 | +5.2% |
| 8 Dec 2017 | +8.1% |
| 15 Dec 2017 | −5.9% |
| 22 Dec 2017 | −7.4% |
| 29 Dec 2017 | +5.1% |
| 5 Jan 2018 | −0.4% |
| 12 Jan 2018 | +1.3% |
| 19 Jan 2018 | −1.9% |
| 25 Jan 2018 | +0.4% |
| 2 Feb 2018 | −1.0% |
| 9 Feb 2018 | +6.5% |
| 16 Feb 2018 | +11.6% |
| 23 Feb 2018 | +3.5% |
| 1 Mar 2018 | +2.4% |
| 9 Mar 2018 | −3.4% |
| 16 Mar 2018 | +1.5% |
| 23 Mar 2018 | +0.2% |
| 28 Mar 2018 | −8.4% |
| 6 Apr 2018 | −7.3% |
| 13 Apr 2018 | −8.2% |
| 20 Apr 2018 | −6.6% |
| 27 Apr 2018 | −7.0% |
| 4 May 2018 | −8.3% |
| 11 May 2018 | −19.0% |
| 18 May 2018 | −18.1% |
| 25 May 2018 | −18.0% |
| 1 Jun 2018 | −12.5% |
| 8 Jun 2018 | +1.7% |
| 15 Jun 2018 | +9.9% |
| 22 Jun 2018 | +12.5% |
| 29 Jun 2018 | +11.5% |
| 6 Jul 2018 | +7.6% |
| 13 Jul 2018 | +9.6% |
| 20 Jul 2018 | +9.8% |
| 27 Jul 2018 | +4.1% |
| 3 Aug 2018 | +9.6% |
| 10 Aug 2018 | +13.1% |
| 17 Aug 2018 | +25.4% |
| 24 Aug 2018 | +27.3% |
| 31 Aug 2018 | +28.7% |
| 7 Sep 2018 | +22.8% |
| 14 Sep 2018 | +13.5% |
| 21 Sep 2018 | +8.1% |
| 28 Sep 2018 | +12.0% |
| 5 Oct 2018 | +13.5% |
| 12 Oct 2018 | +11.0% |
| 19 Oct 2018 | +18.4% |
| 26 Oct 2018 | +8.8% |
| 2 Nov 2018 | +6.0% |
| 9 Nov 2018 | +16.1% |
| 16 Nov 2018 | −7.3% |
| 22 Nov 2018 | −6.7% |
| 30 Nov 2018 | −17.0% |
| 7 Dec 2018 | −31.5% |
| 14 Dec 2018 | −33.6% |
| 21 Dec 2018 | −30.2% |
| 28 Dec 2018 | −32.3% |
| 4 Jan 2019 | −31.8% |
| 11 Jan 2019 | −29.3% |
| 18 Jan 2019 | −41.9% |
| 25 Jan 2019 | −25.3% |
| 1 Feb 2019 | −28.1% |
| 8 Feb 2019 | −27.5% |
| 15 Feb 2019 | −17.6% |
| 22 Feb 2019 | −17.6% |
| 1 Mar 2019 | −11.4% |
| 8 Mar 2019 | +5.9% |
| 15 Mar 2019 | +7.1% |
| 22 Mar 2019 | +6.2% |
| 29 Mar 2019 | +6.5% |
| 5 Apr 2019 | +1.3% |
| 12 Apr 2019 | −2.2% |
| 18 Apr 2019 | +11.7% |
| 26 Apr 2019 | +1.1% |
| 3 May 2019 | +4.7% |
| 10 May 2019 | −1.5% |
| 17 May 2019 | −11.8% |
| 24 May 2019 | −12.5% |
| 31 May 2019 | −15.4% |
| 7 Jun 2019 | −15.4% |
| 14 Jun 2019 | −15.2% |
| 21 Jun 2019 | −21.0% |
| 28 Jun 2019 | −17.3% |
| 5 Jul 2019 | −16.7% |
| 12 Jul 2019 | −9.9% |
| 19 Jul 2019 | −3.6% |
| 26 Jul 2019 | +1.2% |
| 2 Aug 2019 | −2.0% |
| 9 Aug 2019 | −1.5% |
| 16 Aug 2019 | +9.0% |
| 23 Aug 2019 | +11.0% |
| 30 Aug 2019 | +20.5% |
| 6 Sep 2019 | +14.0% |
| 13 Sep 2019 | +14.5% |
| 20 Sep 2019 | +11.6% |
| 27 Sep 2019 | +5.5% |
| 4 Oct 2019 | +5.2% |
| 11 Oct 2019 | −2.5% |
| 18 Oct 2019 | −7.9% |
| 27 Oct 2019 | −12.5% |
| 1 Nov 2019 | −5.8% |
| 8 Nov 2019 | −7.4% |
| 15 Nov 2019 | −9.8% |
| 22 Nov 2019 | −3.7% |
| 29 Nov 2019 | −10.9% |
| 6 Dec 2019 | −6.1% |
| 13 Dec 2019 | −7.2% |
| 20 Dec 2019 | −1.6% |
| 27 Dec 2019 | −1.0% |
| 3 Jan 2020 | +8.5% |
| 10 Jan 2020 | +6.2% |
| 17 Jan 2020 | +8.0% |
| 24 Jan 2020 | +4.2% |
| 1 Feb 2020 | −5.7% |
| 7 Feb 2020 | −2.1% |
| 14 Feb 2020 | −1.5% |
| 20 Feb 2020 | −8.5% |
| 28 Feb 2020 | −11.8% |
| 6 Mar 2020 | +4.1% |
| 13 Mar 2020 | +16.4% |
| 20 Mar 2020 | +16.7% |
| 27 Mar 2020 | +11.0% |
| 3 Apr 2020 | +11.4% |
| 9 Apr 2020 | +29.6% |
| 17 Apr 2020 | +24.8% |
| 24 Apr 2020 | +30.5% |
| 30 Apr 2020 | +33.7% |
| 8 May 2020 | +32.5% |
| 15 May 2020 | +32.7% |
| 22 May 2020 | +37.0% |
| 29 May 2020 | +38.6% |
| 5 Jun 2020 | +27.1% |
| 12 Jun 2020 | +8.8% |
| 19 Jun 2020 | +7.3% |
| 26 Jun 2020 | +15.4% |
| 3 Jul 2020 | +4.2% |
| 10 Jul 2020 | −9.6% |
| 17 Jul 2020 | −9.9% |
| 24 Jul 2020 | −16.6% |
| 31 Jul 2020 | −5.5% |
| 7 Aug 2020 | −9.0% |
| 14 Aug 2020 | −8.3% |
| 21 Aug 2020 | −12.5% |
| 28 Aug 2020 | +1.1% |
| 4 Sep 2020 | −8.3% |
| 11 Sep 2020 | −13.0% |
| 18 Sep 2020 | −1.0% |
| 25 Sep 2020 | −7.2% |
| 1 Oct 2020 | −3.6% |
| 9 Oct 2020 | −8.5% |
| 16 Oct 2020 | −11.2% |
| 23 Oct 2020 | −6.1% |
| 30 Oct 2020 | −19.8% |
| 6 Nov 2020 | −14.7% |
| 14 Nov 2020 | −15.8% |
| 20 Nov 2020 | −16.0% |
| 27 Nov 2020 | −22.0% |
| 4 Dec 2020 | −9.3% |
| 11 Dec 2020 | −5.1% |
| 18 Dec 2020 | −12.2% |
| 24 Dec 2020 | −2.6% |
| 1 Jan 2021 | −4.0% |
| 8 Jan 2021 | −2.3% |
| 15 Jan 2021 | +0.3% |
| 22 Jan 2021 | −1.2% |
| 29 Jan 2021 | +1.2% |
| 5 Feb 2021 | +4.4% |
| 12 Feb 2021 | +3.0% |
| 19 Feb 2021 | +2.9% |
| 26 Feb 2021 | −1.3% |
| 5 Mar 2021 | −6.1% |
| 12 Mar 2021 | −0.8% |
| 19 Mar 2021 | −8.1% |
| 26 Mar 2021 | −7.5% |
| 1 Apr 2021 | −3.9% |
| 9 Apr 2021 | +1.4% |
| 16 Apr 2021 | +7.1% |
| 23 Apr 2021 | +2.5% |
| 30 Apr 2021 | +9.7% |
| 7 May 2021 | +6.4% |
| 14 May 2021 | +8.6% |
| 21 May 2021 | +9.1% |
| 28 May 2021 | +8.6% |
| 4 Jun 2021 | +4.7% |
| 11 Jun 2021 | +1.4% |
| 18 Jun 2021 | +5.5% |
| 25 Jun 2021 | +5.1% |
| 2 Jul 2021 | +2.3% |
| 9 Jul 2021 | −7.2% |
| 16 Jul 2021 | −5.4% |
| 23 Jul 2021 | +0.3% |
| 30 Jul 2021 | +5.7% |
| 6 Aug 2021 | +4.9% |
| 13 Aug 2021 | +2.5% |
| 20 Aug 2021 | +2.0% |
| 27 Aug 2021 | +5.6% |
| 3 Sep 2021 | +6.6% |
| 9 Sep 2021 | +2.8% |
| 17 Sep 2021 | +3.5% |
| 24 Sep 2021 | +2.6% |
| 1 Oct 2021 | +10.3% |
| 8 Oct 2021 | +8.6% |
| 14 Oct 2021 | +6.8% |
| 22 Oct 2021 | +3.1% |
| 29 Oct 2021 | −6.7% |
| 4 Nov 2021 | −10.5% |
| 12 Nov 2021 | −6.0% |
| 18 Nov 2021 | −2.9% |
| 26 Nov 2021 | −2.2% |
| 3 Dec 2021 | −6.6% |
| 10 Dec 2021 | −1.5% |
| 17 Dec 2021 | +2.2% |
| 24 Dec 2021 | +3.4% |
| 31 Dec 2021 | +0.6% |
| 7 Jan 2022 | +0.7% |
| 14 Jan 2022 | +2.8% |
| 21 Jan 2022 | +3.7% |
| 28 Jan 2022 | +4.0% |
| 4 Feb 2022 | +15.6% |
| 11 Feb 2022 | +13.4% |
| 18 Feb 2022 | +12.7% |
| 25 Feb 2022 | +12.3% |
| 4 Mar 2022 | +17.6% |
| 11 Mar 2022 | +21.6% |
| 17 Mar 2022 | +18.2% |
| 25 Mar 2022 | +14.7% |
| 1 Apr 2022 | +7.9% |
| 8 Apr 2022 | +14.9% |
| 13 Apr 2022 | +13.0% |
| 22 Apr 2022 | +14.9% |
| 29 Apr 2022 | +18.1% |
| 6 May 2022 | +7.1% |
| 13 May 2022 | +6.2% |
| 20 May 2022 | +12.4% |
| 27 May 2022 | +9.5% |
| 3 Jun 2022 | +4.9% |
| 10 Jun 2022 | +1.4% |
| 17 Jun 2022 | −1.8% |
| 24 Jun 2022 | +1.3% |
| 1 Jul 2022 | +2.3% |
| 8 Jul 2022 | +2.1% |
| 15 Jul 2022 | −1.6% |
| 22 Jul 2022 | −2.1% |
| 29 Jul 2022 | −1.8% |
| 5 Aug 2022 | −5.1% |
| 12 Aug 2022 | −7.0% |
| 19 Aug 2022 | −13.0% |
| 26 Aug 2022 | −11.4% |
| 2 Sep 2022 | −9.8% |
| 9 Sep 2022 | −11.6% |
| 16 Sep 2022 | −8.3% |
| 23 Sep 2022 | +2.7% |
| 30 Sep 2022 | +4.6% |
| 7 Oct 2022 | +3.3% |
| 14 Oct 2022 | +4.8% |
| 21 Oct 2022 | +5.5% |
| 28 Oct 2022 | +0.8% |
| 4 Nov 2022 | +9.7% |
| 11 Nov 2022 | +9.1% |
| 18 Nov 2022 | +9.4% |
| 25 Nov 2022 | +13.4% |
| 2 Dec 2022 | +16.1% |
| 9 Dec 2022 | +9.4% |
| 16 Dec 2022 | +13.4% |
| 23 Dec 2022 | +3.2% |
| 30 Dec 2022 | +2.7% |
| 6 Jan 2023 | +2.4% |
| 13 Jan 2023 | +3.0% |
| 20 Jan 2023 | +5.3% |
| 27 Jan 2023 | +9.6% |
| 3 Feb 2023 | +2.3% |
| 10 Feb 2023 | +3.3% |
| 17 Feb 2023 | +2.9% |
| 24 Feb 2023 | +1.9% |
| 3 Mar 2023 | −1.1% |
| 10 Mar 2023 | +6.5% |
| 17 Mar 2023 | +3.3% |
| 24 Mar 2023 | +4.2% |
| 31 Mar 2023 | +2.6% |
| 6 Apr 2023 | +2.7% |
| 13 Apr 2023 | +1.2% |
| 21 Apr 2023 | −2.8% |
| 28 Apr 2023 | −8.2% |
| 5 May 2023 | −8.5% |
| 12 May 2023 | −7.6% |
| 19 May 2023 | −11.5% |
| 26 May 2023 | −7.6% |
| 2 Jun 2023 | −3.9% |
| 9 Jun 2023 | −9.3% |
| 16 Jun 2023 | −8.7% |
| 23 Jun 2023 | −11.6% |
| 30 Jun 2023 | −5.9% |
| 7 Jul 2023 | −9.0% |
| 14 Jul 2023 | −7.2% |
| 21 Jul 2023 | −2.3% |
| 28 Jul 2023 | +4.9% |
| 4 Aug 2023 | +7.4% |
| 11 Aug 2023 | +9.2% |
| 18 Aug 2023 | +13.3% |
| 25 Aug 2023 | +6.4% |
| 1 Sep 2023 | +3.0% |
| 8 Sep 2023 | +5.9% |
| 15 Sep 2023 | +8.5% |
| 22 Sep 2023 | +7.7% |
| 29 Sep 2023 | +7.0% |
| 6 Oct 2023 | +4.2% |
| 13 Oct 2023 | +4.4% |
| 20 Oct 2023 | +5.4% |
| 27 Oct 2023 | −1.6% |
| 3 Nov 2023 | −1.3% |
| 12 Nov 2023 | −0.3% |
| 17 Nov 2023 | +1.3% |
| 24 Nov 2023 | +2.5% |
| 1 Dec 2023 | +3.0% |
| 8 Dec 2023 | +2.3% |
| 15 Dec 2023 | −0.1% |
| 22 Dec 2023 | −1.4% |
| 29 Dec 2023 | −4.4% |
| 5 Jan 2024 | +3.2% |
| 12 Jan 2024 | +3.4% |
| 20 Jan 2024 | +0.1% |
| 25 Jan 2024 | +4.8% |
| 2 Feb 2024 | +7.6% |
| 9 Feb 2024 | +17.0% |
| 16 Feb 2024 | +12.2% |
| 23 Feb 2024 | +18.8% |
| 2 Mar 2024 | +20.8% |
| 7 Mar 2024 | +25.2% |
| 15 Mar 2024 | +20.7% |
| 22 Mar 2024 | +25.3% |
| 28 Mar 2024 | +22.3% |
| 5 Apr 2024 | +16.6% |
| 12 Apr 2024 | +11.3% |
| 19 Apr 2024 | +8.2% |
| 26 Apr 2024 | +4.1% |
| 3 May 2024 | +3.7% |
| 10 May 2024 | −6.0% |
| 18 May 2024 | −4.1% |
| 24 May 2024 | −10.9% |
| 31 May 2024 | −13.0% |
| 7 Jun 2024 | −17.9% |
| 14 Jun 2024 | −15.3% |
| 21 Jun 2024 | −20.5% |
| 28 Jun 2024 | −17.0% |
| 5 Jul 2024 | −12.4% |
| 12 Jul 2024 | −11.2% |
| 19 Jul 2024 | −7.6% |
| 26 Jul 2024 | +1.7% |
| 2 Aug 2024 | +4.2% |
| 9 Aug 2024 | +5.9% |
| 16 Aug 2024 | +3.7% |
| 23 Aug 2024 | +8.3% |
| 30 Aug 2024 | +12.0% |
| 6 Sep 2024 | +13.9% |
| 13 Sep 2024 | +14.7% |
| 20 Sep 2024 | +18.5% |
| 27 Sep 2024 | +21.9% |
| 4 Oct 2024 | +19.1% |
| 11 Oct 2024 | +18.6% |
| 18 Oct 2024 | +22.1% |
| 25 Oct 2024 | +11.8% |
| 1 Nov 2024 | +6.5% |
| 8 Nov 2024 | +7.6% |
| 14 Nov 2024 | +7.3% |
| 22 Nov 2024 | +5.0% |
| 29 Nov 2024 | +0.5% |
| 6 Dec 2024 | −0.3% |
| 13 Dec 2024 | +1.9% |
| 20 Dec 2024 | +5.0% |
| 27 Dec 2024 | +3.3% |
| 3 Jan 2025 | +2.6% |
| 10 Jan 2025 | +2.8% |
| 17 Jan 2025 | −0.2% |
| 24 Jan 2025 | +4.6% |
| 1 Feb 2025 | −0.8% |
| 7 Feb 2025 | +1.3% |
| 14 Feb 2025 | +2.0% |
| 21 Feb 2025 | +1.6% |
| 28 Feb 2025 | +1.8% |
| 7 Mar 2025 | +2.4% |
| 13 Mar 2025 | +1.9% |
| 21 Mar 2025 | +3.7% |
| 28 Mar 2025 | −1.8% |
| 4 Apr 2025 | +0.8% |
| 11 Apr 2025 | −4.8% |
| 17 Apr 2025 | −5.9% |
| 25 Apr 2025 | −5.6% |
| 2 May 2025 | +3.7% |
| 9 May 2025 | −7.9% |
| 16 May 2025 | −7.6% |
| 23 May 2025 | −9.1% |
| 30 May 2025 | −7.3% |
| 6 Jun 2025 | −10.8% |
| 13 Jun 2025 | −9.6% |
| 20 Jun 2025 | −16.2% |
| 27 Jun 2025 | −13.4% |
| 4 Jul 2025 | −17.7% |
| 11 Jul 2025 | −10.6% |
| 18 Jul 2025 | −8.7% |
| 25 Jul 2025 | −9.5% |
| 1 Aug 2025 | −13.6% |
| 8 Aug 2025 | −9.9% |
| 14 Aug 2025 | −7.2% |
| 22 Aug 2025 | −2.4% |
| 29 Aug 2025 | −5.2% |
| 5 Sep 2025 | −4.0% |
| 12 Sep 2025 | −6.5% |
| 19 Sep 2025 | +0.0% |
| 26 Sep 2025 | −3.4% |
| 3 Oct 2025 | −0.8% |
| 10 Oct 2025 | +0.3% |
| 17 Oct 2025 | −2.3% |
| 24 Oct 2025 | −4.0% |
| 31 Oct 2025 | −0.7% |
| 7 Nov 2025 | +1.6% |
| 14 Nov 2025 | +3.8% |
| 21 Nov 2025 | +3.2% |
| 28 Nov 2025 | +11.1% |
| 5 Dec 2025 | +11.8% |
| 12 Dec 2025 | +10.7% |
| 19 Dec 2025 | +2.5% |
| 26 Dec 2025 | +4.3% |
| 2 Jan 2026 | +2.0% |
| 9 Jan 2026 | +3.1% |
| 16 Jan 2026 | +3.3% |
| 23 Jan 2026 | −0.3% |
| 1 Feb 2026 | −3.7% |
| 6 Feb 2026 | +0.4% |
| 13 Feb 2026 | −2.3% |
| 20 Feb 2026 | −0.8% |
| 27 Feb 2026 | +0.3% |
| 6 Mar 2026 | +3.6% |
| 13 Mar 2026 | +7.2% |
| 20 Mar 2026 | +11.8% |
| 27 Mar 2026 | +16.6% |
| 2 Apr 2026 | +5.8% |
| 10 Apr 2026 | −0.6% |
| 17 Apr 2026 | −0.3% |
| 24 Apr 2026 | +0.2% |
| 30 Apr 2026 | +13.6% |
| 8 May 2026 | +14.3% |
| 15 May 2026 | +15.4% |
| 22 May 2026 | +10.2% |
| 29 May 2026 | +2.5% |
| 4 Jun 2026 | −1.0% |
| 5 Jun 2026 | −3.6% |
| 10 Jun 2026 | −4.7% |
| 12 Jun 2026 | −7.2% |
| 17 Jun 2026 | +2.9% |
| 19 Jun 2026 | +8.7% |
| 24 Jun 2026 | +11.3% |
| 25 Jun 2026 | +13.9% |
| 1 Jul 2026 | +2.5% |
| 3 Jul 2026 | −0.3% |
| 10 Jul 2026 | −0.6% |
| 17 Jul 2026 | +1.7% |
| 24 Jul 2026 | +6.8% |
| 31 Jul 2026 | +7.4% |
| 7 Aug 2026 | +3.6% |
| 14 Aug 2026 | +3.6% |
| 21 Aug 2026 | +1.1% |
| 28 Aug 2026 | +3.8% |
| 4 Sep 2026 | +2.8% |
| 11 Sep 2026 | −0.8% |
| 18 Sep 2026 | −0.2% |
| 25 Sep 2026 | +2.2% |
| 1 Oct 2026 | +0.7% |
| 9 Oct 2026 | −2.7% |
| 16 Oct 2026 | −4.4% |
| 23 Oct 2026 | −3.5% |
| 30 Oct 2026 | −4.0% |
| 6 Nov 2026 | −3.3% |
| 12 Nov 2026 | −1.7% |
Over the last 11 years the share price moved +117% while the NIFTY 500 moved +276%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Sun Pharma this quarter?
Three changes stood out: foreign funds (FIIs) cut their stake for 7 quarters in a row, indian funds and insurers (DIIs) raised their stake for 7 quarters in a row and revenue up on a year earlier for 12 quarters in a row (every quarter we can compare).
Foreign funds (FIIs) cut their stake for 7 quarters in a row
From 18% to 14.4% of the company by the September 2026 quarter.
Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row
From 18.4% to 22.3% of the company by the September 2026 quarter.
Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)
In the September 2026 quarter revenue was ₹16,199 crore, +11.9% on a year earlier.
Why: Revenue rose because India sales grew on more volume and a wider prescriber base, more than offsetting weaker US sales.
Next results: check whether Ilumya US prescriptions recover after the slowdown, since management expects its actions and a new use to bring back usual growth.
From the earnings call on 30 Oct 2026.
What are Sun Pharma's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Sun Pharma reported revenue of ₹16,199 crore, up 11.9% from ₹14,478 crore a year earlier, and a profit of ₹1,995 crore, down 36.2% from ₹3,125 crore.
Sun Pharma results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹16,199 crore | ₹14,478 crore | +11.9% |
| Profit | ₹1,995 crore | ₹3,125 crore | −36.2% |
| Earnings per share | ₹8.29 | ₹13.00 | −36.2% |
| Operating margin | 29.3% | 31.3% | −2.0 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Sun Pharma's management discussed these results on a call held on 30 October 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Sun Pharma share price history?
Sun Pharma closed at ₹1,885.00 on 12 November 2026, up 7.3% from ₹1,757.10 a year earlier (14 November 2025) and up 133.7% over five years. Its highest weekly close since March 2016 was ₹1,990.50 on 31 July 2026.
Sun Pharma share price: then and now
| When | Close | Change to 12 Nov 2026 |
|---|---|---|
| 1 week ago · 5 Nov 2026 | ₹1,829.00 | +3.1% |
| 1 month ago · 12 Oct 2026 | ₹1,760.00 | +7.1% |
| 6 months ago · 15 May 2026 | ₹1,878.20 | +0.4% |
| 1 year ago · 14 Nov 2025 | ₹1,757.10 | +7.3% |
| 3 years ago · 12 Nov 2023 | ₹1,180.60 | +59.7% |
| 5 years ago · 12 Nov 2021 | ₹806.50 | +133.7% |
| 10 years ago · 11 Nov 2016 | ₹688.00 | +174.0% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹868.20 | +117.1% |
| Highest weekly close since March 2016, also the 52-week high · 31 Jul 2026 | ₹1,990.50 | −5.3% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹338.25 | +457.3% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹1,610.10 | +17.1% |
Weekly closing prices. Each change is the move from that price to the 12 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
563 weekly closes from 11 March 2016 to 12 November 2026.
What is the latest news on Sun Pharma?
12 Nov 2026: Sun Pharma closed at ₹1,885.00, up 3.1% on the week and up 7.1% on the month. 30 Oct 2026: Sun Pharma held its results call for July to September 2026. Management guided: FY27 sales growth high single-digit reiterated.
Earlier
- Results for July to September 2026: Revenue up 11.9% and profit down 36.2% on a year earlier.
- Our read, 22 Aug 2026: Sun Pharma has reported its July to September 2026 results since this read was written. The earlier read is kept below, closed, until we update it.
- 7 Jul 2026: ex-date for a dividend of ₹5 a share.
- 5 Feb 2026: ex-date for an interim dividend of ₹11 a share.
Our read of the business
Show the earlier read
India formulations grew 16.0% year-on-year in April to June 2026, while innovative medicines delivered US$351 million of sales and US generics declined 9.7% year-on-year. The Organon transaction adds scale, biosimilars and women's health but would raise net debt to operating profit to 2.3x at close and requires execution against a flat established-brands base.
India formulations grew 16.0% year-on-year in April to June 2026, while innovative medicines delivered US$351 million of sales and US generics declined 9.7% year-on-year. The Organon transaction adds scale, biosimilars and women's health but would raise net debt to operating profit to 2.3x at close and requires execution against a flat established-brands base.
April to June 2026: India and innovative-medicines growth offset US generic erosion; reported revenue grew 17.7% year-on-year.
Our read after the April to June 2026 results, written 22 August 2026.
What dividend does Sun Pharma pay?
Sun Pharma paid ₹16 a share in regular dividends in the 12 months to 12 November 2026 (2 payments), a yield of 0.85% at the ₹1,885.00 close on 12 November 2026. The last was a dividend of ₹5 a share, ex-date 7 July 2026.
Sun Pharma dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 7 Jul 2026Dividend | ₹5 | Dividend | same day |
| 5 Feb 2026Interim | ₹11 | Interim | same day |
| 7 Jul 2025Dividend | ₹5.50 | Dividend | same day |
| 6 Feb 2025Interim | ₹10.50 | Interim | same day |
| 12 Jul 2024Dividend | ₹5 | Dividend | same day |
| 9 Feb 2024Interim | ₹8.50 | Interim | same day |
| 28 Jul 2023Dividend | ₹4 | Dividend | same day |
| 8 Feb 2023Interim | ₹7.50 | Interim | same day |
| 19 Aug 2022Dividend | ₹3 | Dividend | 22 Aug 2022 |
| 9 Feb 2022Interim | ₹7 | Interim | 10 Feb 2022 |
| 23 Aug 2021Dividend | ₹2 | Dividend | — |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. Sun Pharmaceutical Industries Ltd paid out 33% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.
From the exchange corporate-actions record, read 12 November 2026.
What did Sun Pharma management say on the latest results call?
On the call for July to September 2026, held on 30 October 2026, Sun Pharma's management guided: FY27 sales growth high single-digit reiterated.
“It is really a variety of things. I think there is a bit of market saturation, but frankly, part of it is execution as well.”Richard Asfalg, on the call for July to September 2026
What management guided
- FY27 R&D at 6-7% of sales with sharp second-half ramp.
- Organon close in January to March 2027 to early 2027 subject to remaining conditions.
- Psoriatic arthritis soft launch in November with full launch in following months.
- Ilumya return to typical growth over next few quarters on interventions plus new indication.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 30 October 2026.
What is the future of Sun Pharma? What is changing in the business?
Sun Pharma has reported its July to September 2026 results since this read was written. The earlier read is kept below, closed, until we update it.
Show the earlier read
What is changing at Sun Pharma, from the latest results and calls: global innovative specialty portfolio scale, india domestic market leadership & volume outperformance and generic semaglutide commercial scaling.
- Global Innovative Specialty Portfolio Scale. Innovative medicines reached US$351 million in April to June 2026, up 12.8% year-on-year and 21.9% of consolidated sales. ⚠ estimate
- India Domestic Market Leadership & Volume Outperformance. India formulations grew 16.0% year-on-year to ₹54,749 million with 8.5% market share. ⚠ estimate
- Generic Semaglutide Commercial Scaling. Sun became the number-two generic Semaglutide injectable player in India and remains the only Indian provider of an auto-injector. ⚠ estimate
- Organon Global Scale & Platform Transformation. The proposed Organon transaction would create a US$12.4 billion revenue entity and goal US$350 million of cost synergies. ⚠ estimate
We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.
Our read after the April to June 2026 results, written 22 August 2026.
What could change the Sun Pharma story? What are the risks?
Sun Pharma has reported its July to September 2026 results since this read was written. The earlier read is kept below, closed, until we update it.
Show the earlier read
Price competition or device-component constraints prevent commercial uptake.
Each change stops working if
- Generic Semaglutide Commercial Scaling: Price competition or device-component constraints prevent commercial uptake.
- Organon Global Scale & Platform Transformation: Closing fails, synergy realization is delayed, or established-brand revenue declines faster than planned.
The main risks
- Post-Acquisition Balance Sheet Leverage: Net debt to operating profit would rise to 2.3x post-close, with deleveraging dependent on combined free cash flow. ✓ fact
- US Generic Revenue Erosion & Site Compliance Delays: US sales declined 9.7% year-on-year in April to June 2026 as generic erosion outweighed innovative-medicines growth. ✓ fact
- Effective Tax Rate Normalization: The effective tax rate has normalized toward 25%, creating a continuing profit headwind versus historical low-tax periods. ✓ fact
- Transaction Closing Uncertainty & Shareholder Approval: Organon closing remains subject to shareholder and regulatory approvals. ✓ fact
Our read after the April to June 2026 results, written 22 August 2026.
What to watch in Sun Pharma's next results?
When Sun Pharma reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ilumya US prescription trend over next few quarters - check whether interventions plus new indication restore typical growth.
| What to check (from the call) |
|---|
| Ilumya US prescription trend over next few quarters - check whether interventions plus new indication restore typical growth. |
| Second-half research spend pace - check catch-up toward full-year range on trial recruitment and infrastructure. |
| Organon remaining approvals and Day-1 readiness - check close tracking communicated window without slippage. |
| Lerodalcibep country pricing progress and first commercial launch signals - check pre-launch to launch conversion. |
Which stock lists is Sun Pharma on?
Sun Pharma is on 2 of our India lists: Nifty 50 companies and Pharma stocks.
Is Sun Pharma profitable?
Sun Pharmaceutical Industries Ltd earned ₹1,995 Cr of net profit in the Sep 2026 quarter, −36.2% on the same quarter a year earlier. Full-year FY26 profit was ₹11,509 Cr. Over 10 years profit has grown 7.4% a year on average. The Sep 2026 quarter's profit is 12.3% of that quarter's revenue. The same quarter a year earlier earned ₹3,125 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
For the full year, FY26 profit was ₹11,509 Cr (+5.0% on the year before).
Why profit moved: revenue changed +11.9% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.
On average over the last four quarters, profit changed +8.1% and revenue +12.2%. Profit is growing slower than sales: rising costs are taking part of the growth.
FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported.
FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
How much revenue does Sun Pharma make, and is it growing?
Sun Pharmaceutical Industries Ltd reported ₹16,199 Cr of revenue in the Sep 2026 quarter, +11.9% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.5% a year on average. The last full year, FY26, came in at ₹58,462 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. India formulations represented 36.1% of consolidated sales in Q1 FY27. PharmaTrac growth was 30.4%; management stated volume plus new products contributed the majority and five products were launched.
The last four reported quarters add to ₹61,632 Cr.
FY26 revenue was ₹58,462 Cr, +11.2% on the year before.
Recent pace: the last four quarters grew +12.2% on average, against 7.5% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +12.1%, against +10.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +4.8%, against −0.6% a year (accelerating).
FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported.
FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Watch next
- Metric
- India Domestic Market Leadership & Volume Outperformance
- Threshold
- India market-share losses or growth below the industry rate persist for multiple quarters.
- Which result
- the next result
How much of every ₹100 of sales does Sun Pharma keep?
Sun Pharmaceutical Industries Ltd's operating margin was 29.3% in the Sep 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 21.3% and 43.6%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. Organon contributes US$6.2 billion revenue, stable 30% EBITDA margin and approximately US$1 billion annual free cash flow before financing. Cost synergies are planned across procurement, G&A and supply chain over two to four years, subject to closing and execution.
Why the margin moved: operating margin changed −2.0 percentage points on the year while gross margin changed +1.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged.
FY27-Q1. revenue ₹15,300 Cr and profit ₹2,901 Cr as reported.
FY27-Q2. revenue ₹16,199 Cr and profit ₹1,995 Cr as reported.
Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.
Watch next
- Metric
- Organon Global Scale & Platform Transformation
- Threshold
- Closing fails, synergy realization is delayed, or established-brand revenue declines faster than planned.
- Which result
- the next result
Is Sun Pharma's profit turning into cash?
Over the last 3 years, 120% of Sun Pharmaceutical Industries Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹12,419 Cr of operating cash against ₹11,509 Cr of profit. After ₹3,609 Cr of spending on assets, ₹8,810 Cr was left over as free cash.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 120% of profit came in as cash: the cash cycle got 82 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.
What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.
Where does Sun Pharma's cash go?
Sun Pharmaceutical Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 228 days in FY26, down from 310 days in FY21. It spent ₹7,940 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 363 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
Why this happened. The portfolio grew from US$400 million in 2021 to US$700 million currently. Commercial execution depends on reimbursement, interchangeability and pricing dynamics.
At FY26 sales of ₹58,462 Cr, each day of that cycle ties up about ₹160 Cr, so roughly ₹36,519 Cr is tied up in the business at any time.
FY26: customers took 97 days to pay and stock sat for 363 days, about 11.9 months of sales sitting as stock, for a full cycle of 228 days, shorter than FY21's 310.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 363 days. Customers pay about 97 days after that. Suppliers are paid at 232 days. Together that makes the 228-day cycle.
Spending on assets: ₹7,940 Cr over the last 3 years, against ₹8,070 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹3,052 Cr (FY26): assets paid for that are not earning yet.
In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.
Watch next
- Metric
- Biosimilar Commercial Platform Expansion
- Threshold
- Biosimilar reimbursement and pricing reduce net realizations faster than portfolio expansion.
- Which result
- the next result
What is Sun Pharma's P/E ratio, and how does it compare with its own history?
Sun Pharmaceutical Industries Ltd's P/E is 41.2×, near the high end of its own history: higher than 95% of past readings. Its usual P/E (the middle reading) is 30.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹45.70.
Why the multiple is where it is: over the past year earnings per share moved +4.8% while the price moved +7.3%. The price did better than earnings, which pushed the multiple up within its own range.
Where the price move came from: over 3 years the price moved +16.9% a year; about +8.7% a year came from earnings growth and about +8.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.
What growth does the Sun Pharma share price assume?
Worked out from its price on 26 August 2026, Sun Pharmaceutical Industries Ltd's share price assumed profit growth of about 21.1% a year. Over the past 10 years its profit actually grew 7.4% a year. Today its P/E is 41.2×, higher than 95% of its own last 11 years.
This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.
This is a one-day reading, taken on 26 August 2026. Every other number on this page, the multiple included, uses the latest price as of 12 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.
Is the Sun Pharma business getting better or worse?
Sun Pharmaceutical Industries Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 17.5% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: steady growth with healthy returns is how a business compounds over time.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +11.2% | +10.0% | +11.8% | +7.5% |
| Profit | +5.0% | +10.6% | +38.3% | +7.4% |
| EPS | +5.0% | +10.6% | +31.6% | +9.7% |
| Share price | +7.3% | +16.9% | +18.5% | +10.6% |
What is the Sun Pharma story, and has it been checked?
Sun Pharmaceutical Industries Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: mid expansion at peak margin.
NOT YET CHECKED
The test written in advance. Post-Acquisition Balance Sheet Leverage. Measured by: Post-Acquisition Balance Sheet Leverage Combined entity free cash flow and net debt in the first two quarters after closing. by the next result.
The test written in advance. Management Guidance Credibility & Strategy Contradictions. Measured by: Management Guidance Credibility & Strategy Contradictions Integration-office disclosure and consistent post-close capital-allocation communication. by the next result.
What the company does. India formulations grew 16.0% year-on-year in Q1 FY27, while innovative medicines delivered US$351 million of sales and US generics declined 9.7% year-on-year. The Organon transaction adds scale, biosimilars and women's health but would raise net debt to EBITDA to 2.3x at close and requires execution against a flat established-brands base.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters | What to watch |
|---|---|---|---|
| Global Innovative Specialty Portfolio Scale | HIGH | Innovative medicines reached US$351 million in Q1 FY27, up 12.8% year-on-year and 21.9% of consolidated sales. | — |
| India Domestic Market Leadership & Volume… | HIGH | India formulations grew 16.0% year-on-year to Rs 54,749 million with 8.5% market share. | India market-share losses or growth below the industry rate persist for multiple quarters. |
| Generic Semaglutide Commercial Scaling | MEDIUM | Sun became the number-two generic Semaglutide injectable player in India and remains the only Indian provider of an auto-injector. | Price competition or device-component constraints prevent commercial uptake. |
| Organon Global Scale & Platform… | HIGH | The proposed Organon transaction would create a US$12.4 billion revenue entity and goal US$350 million of cost synergies. | Closing fails, synergy realization is delayed, or established-brand revenue declines faster than planned. |
| Biosimilar Commercial Platform Expansion | MEDIUM | Organon provides a US$700 million biosimilar portfolio with 13% historical CAGR and an in-licensing platform. | Biosimilar reimbursement and pricing reduce net realizations faster than portfolio expansion. |
Everything further down this page is evidence for or against these.
FY26-Q3FY27-Q2
What the surface reading misses. The surface reading is: ROCE of 20.5% exceeds the stated ROE of 16.0%. The research reads it further: These returns are standalone figures; proposed Organon leverage and goodwill could alter post-close return metrics.
- 1 · Operating leveragequiet
- 2 · Value-added mixquiet
- 3 · Management changequiet
- 4 · Paying down debtquiet
- 5 · Regulatory approvalquiet
- 6 · Order-book winsquiet
- 7 · Consolidationquiet
- 8 · Demerger or value unlockquiet
- 9 · Buybackquiet
- 10 · New geographiesquiet
- 11 · More business from existing customersquiet
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsbuilding
- 16 · Asset qualityquiet
Lever 15 · Market-share gains: building. India formulations grew 16.0% year-on-year to Rs 54,749 million with 8.5% market share. What proves it keeps working: India Domestic Market Leadership & Volume Outperformance. It stops working if India market-share losses or growth below the industry rate persist for multiple quarters.
Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
Did Sun Pharma management deliver what it promised?
What Sun Pharmaceutical Industries Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Ilumya Outlook Reversed · 30 October 2026. In Jul 2026, management characterized US innovative medicines as expected to continue healthy growth and specifically said Ilumya was doing well. In Oct 2026, management instead identified an Ilumya slowdown as a key driver of slower global innovative-medicine growth and later attributed it partly to market saturation and execution, a material change in outlook that merits explanation.
Conflicting Organon Closing Fiscal Year · 30 October 2026. In Jul 2026, management stated that the Organon acquisition would be completed in Q4 FY27, and the Oct 2026 prepared remarks repeated that timeline. However, the Oct 2026 Q&A referred to closing in Q4 FY25 when discussing the final estimate of acquisition-related costs, creating a material fiscal-period conflict for modeling transaction timing and exceptional expenses.
M&A Strategy Pivot - From Disciplined Tuck-ins to Transformative Mega-Deal · 27 April 2026. In the Jan 2026 call, Dilip Shanghvi explicitly described Sun's M&A posture as pursuing tuck-ins or smaller acquisitions in emerging markets and stressed that acquisitions would only be considered if manageable without diluting focus on organic growth. Just three months later in the Apr 2026 call, Sun announced the acquisition of Organon at an enterprise value of $11.75 billion - a company of comparable scale to Sun itself - while accepting 2.3x net debt to EBITDA, a complete departure from the stated approach with no prior communication of any strategy pivot of this magnitude.
Dividend Policy - From Active Increase to Declared Uncertainty · 27 April 2026. In the Jan 2026 call, the Board declared an increased interim dividend of Rs.11 per share for FY26, up from Rs.10.5 the prior year, projecting a clear upward dividend trajectory for shareholders.
Every quote above is taken word for word from the company’s own earnings calls.
How much does Sun Pharma earn on its capital?
Sun Pharmaceutical Industries Ltd earned a ROCE of 21% in FY26. That is up from a low of 10% in FY18. Its return on capital used (ROIC) is 6.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.7% net margin and 0.54× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 19.7% net margin × 0.54× asset turnover × 1.30× leverage (assets divided by equity) ≈ 13.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.
The key test, return on capital used minus the cost of capital: 18.4% − 12.0% = +6.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.
The 18.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 20.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.
Does Sun Pharma have too much debt?
Sun Pharmaceutical Industries Ltd has total debt of ₹3,241 Cr against shareholder equity of ₹89,280 Cr as of Sep 2026, so its debt is 0.04× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.06 in FY26. So the returns on this page come from the business, not from borrowed money.
Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.
What is the Sun Pharma shareholding pattern?
Domestic institutions raised their stake in Sun Pharmaceutical Industries Ltd by 3.8 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 22.3% of the company. Foreign institutions moved −3.7 points over the same period, to 14.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Over the last two years: Domestic institutions: +3.8 points over 8 quarters, to 22.3%; Foreign institutions: −3.7 points over 8 quarters, to 14.4%; Promoters: −1.8 points over 8 quarters, to 52.7%.
Why the owners changed: foreign institutions moved −3.7 points and domestic institutions +3.8 points over 8 quarters, while promoters moved −1.8 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company.
How far is Sun Pharma from balance-sheet trouble?
For Sun Pharmaceutical Industries Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Sun Pharma rank in its industry?
40.9 out of 100, rank 32 of 44 in Pharma - Formulators, with 100% of the evidence available.
Sun Pharmaceutical Industries Ltd scores 40.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 32. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value.
The four parts add up to the total exactly: 12.2 + 17.1 + 5.2 + 6.4 = 40.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Sun Pharma compared with?
Sun Pharma ranks 32 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 40.9 out of 100.
- 1Marksans Pharma LtdMARKSANS · leader · Most evidence points up · 78% evidence75.5out of 100
How the score adds up
Growth & earnings 30.6/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 14.9/20 · P/E 25.9× · PEG 1 · 65% evidenceRelative strength 12.0/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 28.2% · 1 year 66.3% · 25% evidence · 12 of 12 weeks aheadExact sum: 30.6 + 18 + 14.9 + 12 = 75.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.5out of 100
How the score adds up
Growth & earnings 26.4/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.1/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.1× · PEG — · 15% evidenceRelative strength 18.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.8% · Strength vs NIFTY 500 (same reading) 28.5% · 1 year 68.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 26.4 + 18.1 + 10 + 18 = 72.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 3Fredun Pharmaceuticals LtdMost evidence points up · 60% evidence68.8out of 100
How the score adds up
Growth & earnings 34.6/43.75 · Revenue 62.6% · Profit 82.8% · Operating margin change 1 points · 95% evidenceCapital efficiency 22.1/31.25 · ROCE 21.5% (year to Mar 2026) · Operating margin 16% · 95% evidenceValuation 12.1/25 · P/E 47.2× · PEG — · 15% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 34.6 + 22.1 + 12.1 = 68.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. - 4Rubicon Research LtdRUBICON · leader · Most evidence points up · 87% evidence67.7out of 100
How the score adds up
Growth & earnings 24.4/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 7.9/20 · P/E 87.3× · PEG 2.18 · 65% evidenceRelative strength 16.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 30.3% · Strength vs NIFTY 500 (same reading) 45.1% · 1 year 140.6% · 70% evidence · 11 of 12 weeks aheadExact sum: 24.4 + 18.8 + 7.9 + 16.6 = 67.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 5Accent Microcell LtdACCENTMIC · leader · Most evidence points up · 65% evidence67.6out of 100
How the score adds up
Growth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 9.8/20 · P/E 25.7× · PEG — · 50% evidenceRelative strength 14.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 15.2% · Strength vs NIFTY 500 (same reading) 29.9% · 1 year 97.5% · 100% evidence · 12 of 12 weeks aheadExact sum: 21.8 + 21.6 + 9.8 + 14.4 = 67.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Ajanta Pharma LtdAJANTPHARM · losing its lead · Most evidence points up · 100% evidence66.4out of 100
How the score adds up
Growth & earnings 30.5/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 8.7/20 · P/E 32.9× · PEG 1.94 · 100% evidenceRelative strength 6.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -8.7% · Strength vs NIFTY 500 (same reading) 5.1% · 1 year 31.7% · 100% evidence · 10 of 12 weeks aheadExact sum: 30.5 + 21.1 + 8.7 + 6.1 = 66.4 · What this means: Earnings are strong; relative strength in its sector is -8.7% and the one-year return is 31.7%. - 7Kwality Pharmaceuticals LtdMost evidence points up · 63% evidence66.4out of 100
How the score adds up
Growth & earnings 36.5/43.75 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 83% evidenceCapital efficiency 22.0/31.25 · ROCE 24.1% (year to Mar 2026) · Operating margin 25.3% · 95% evidenceValuation 7.9/25 · P/E 50.5× · PEG — · 50% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 36.5 + 22 + 7.9 = 66.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. - 8Ipca Laboratories LtdIPCALAB · turning · Most evidence points up · 82% evidence66.2out of 100
How the score adds up
Growth & earnings 24.6/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.0/20 · P/E 34.4× · PEG — · 50% evidenceRelative strength 14.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.3% · Strength vs NIFTY 500 (same reading) 15.3% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.6 + 15.7 + 11 + 14.9 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.7out of 100
How the score adds up
Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.7/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.6/20 · P/E 42.2× · PEG — · 50% evidenceRelative strength 14.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 47.4% · Strength vs NIFTY 500 (same reading) 60.8% · 1 year 296.6% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.7 + 6.6 + 14.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Alembic Pharmaceuticals LtdAPLLTD · turning · Evidence leans up · 85% evidence64.7out of 100
How the score adds up
Growth & earnings 26.2/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.3/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.6/20 · P/E 24.4× · PEG 1.34 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 18.9% · 1 year 15.8% · 25% evidence · 8 of 12 weeks aheadExact sum: 26.2 + 12.3 + 14.6 + 11.6 = 64.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Mankind Pharma LtdMANKIND · turning · Evidence leans up · 100% evidence64.6out of 100
- 12FDC LtdFDC · turning · Evidence leans up · 75% evidence61.3out of 100
- 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.8out of 100
- 14Corona Remedies LtdCORONA · turning · Evidence leans up · 73% evidence58.4out of 100
- 15ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.5out of 100
- 16Amrutanjan Health Care LtdAMRUTANJAN · basing · Evidence leans up · 90% evidence55.7out of 100
- 17Gufic BioSciences LtdGUFICBIO · losing its lead · Evidence leans up · 71% evidence55.3out of 100
- 18Akums Drugs & Pharmaceuticals LtdAKUMS · leader · Evidence leans up · 75% evidence54.8out of 100
- 19Zydus Lifesciences LtdZYDUSLIFE · leader · Evidence leans up · 90% evidence54.5out of 100
- 20Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 86% evidence54.2out of 100
- 21Lupin LtdLUPIN · quiet · Evidence leans up · 83% evidence54.1out of 100
- 22Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence52.8out of 100
- 23Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence52.2out of 100
- 24Kilitch Drugs (India) LtdKILITCH · losing its lead · Evidence leans up · 82% evidence50.9out of 100
- 25Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 75% evidence50.4out of 100
- 26Influx Healthtech LtdINFLUX · quiet · Too little evidence to rank firmly · 51% evidence49.3out of 100
- 27Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 78% evidence48.5out of 100
- 28J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence46.5out of 100
- 29Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.3out of 100
- 30Bajaj Healthcare LtdBAJAJHCARE · quiet · Evidence leans down · 90% evidence41.9out of 100
- 31Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.4out of 100
- 32Sun Pharmaceutical Industries Ltd this pageSUNPHARMA · quiet · Evidence leans down · 100% evidence40.9out of 100
How the score adds up
Growth & earnings 12.2/35 · Revenue 12.1% · Profit 4.8% · Operating margin change -2 points · 100% evidenceCapital efficiency 17.1/25 · ROCE 20.5% (year to Mar 2026) · Operating margin 29.3% · 100% evidenceValuation 5.2/20 · P/E 41.2× · PEG 3.65 · 100% evidenceRelative strength 6.4/20 · Strength vs its industry (price vs its 52-week average, weekly) -12.9% · Strength vs NIFTY 500 (same reading) 1.2% · 1 year 7.3% · 100% evidence · 2 of 12 weeks aheadExact sum: 12.2 + 17.1 + 5.2 + 6.4 = 40.9 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. - 33RPG Life Sciences LtdRPGLIFE · quiet · Evidence leans down · 90% evidence40.7out of 100
- 34Indoco Remedies LtdINDOCO · basing · Too little evidence to rank firmly · 52% evidence37.3out of 100
- 35Bharat Parenterals LtdToo little evidence to rank firmly · 52% evidence36.4out of 100
- 36Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Evidence leans down · 100% evidence36.1out of 100
- 37Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Most evidence points down · 64% evidence34.0out of 100
- 38Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 86% evidence33.7out of 100
- 39Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence33.1out of 100
- 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence31.3out of 100
- 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence31.2out of 100
- 42Biocon LtdBIOCON · quiet · Most evidence points down · 100% evidence24.3out of 100
- 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.5out of 100
- 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.6out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Pharma - Formulators, all 44 compared on one page.
Which companies are close to Sun Pharma in size?
Sun Pharma is the largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 12 November 2026 close). It is the largest. Just below it: Torrent Pharmaceuticals, Zydus Lifesciences, Dr Reddys Laboratories, Cipla, Mankind Pharma and Aurobindo Pharma.
Pharma - Formulators companies close in size
- Sun Pharmaceutical Industries Ltd ₹4,52,274 crore
- Torrent Pharmaceuticals Ltd ₹1,79,808 crore
- Zydus Lifesciences Ltd ₹1,20,299 crore
- Dr Reddys Laboratories Ltd ₹1,15,819 crore
- Cipla Ltd ₹1,13,773 crore
- Mankind Pharma Ltd ₹1,08,986 crore
- Aurobindo Pharma Ltd ₹1,03,982 crore
All 44 Pharma - Formulators companies, largest first
Companies close in size in other industries
- Infosys Ltd ₹4,67,191 crore · IT - Software
- Hindustan Unilever Ltd ₹4,63,809 crore · FMCG - Personal Care
- Sun Pharmaceutical Industries Ltd ₹4,52,274 crore
- Adani Ports & Special Economic Zone Ltd ₹4,44,664 crore · Marine Port & Services
- Titan Company Ltd ₹4,36,959 crore · Diamond, Gems & Jewellery
What else do people ask about Sun Pharma?
What were Sun Pharma's latest quarterly results?
Sun Pharmaceutical Industries Ltd reported revenue of ₹16,199 Cr and net profit of ₹1,995 Cr for the Sep 2026 quarter. Revenue rose 11.9% and profit fell 36.2% compared with a year earlier. Earnings per share were ₹8.29.
The operating margin was 29.3%, 2.0 percentage points lower than a year earlier (as of 12 November 2026).
What is Sun Pharma's market cap?
Sun Pharmaceutical Industries Ltd's market capitalisation is ₹4,52,274 Cr at a share price of ₹1,885.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 12 November 2026).
How is Sun Pharma performing?
Sun Pharmaceutical Industries Ltd's share price has been stalling near its high for 3 weeks. In its latest quarter, revenue rose 11.9% and profit fell 36.2% compared with a year earlier.
Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running (as of 12 November 2026).
Will Sun Pharma's share price go up?
This page does not forecast Sun Pharmaceutical Industries Ltd's share price. What it shows instead: the share price is ₹1,885.00, and it has been stalling near its high for 3 weeks. Its P/E of 41.2× is higher than 95% of its own last 11 years (as of 12 November 2026).
Where is Sun Pharma in its business cycle?
Sun Pharmaceutical Industries Ltd's FY26 operating margin was 28.2%, against a 13-year range of 21.3% to 43.6%. The latest quarter was 29.3%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 12 November 2026).
What could break the Sun Pharma story?
The main question: domestic institutions moved +3.8 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 12 November 2026).
Is Sun Pharma a stock worth studying right now?
What the numbers show: Sun Pharmaceutical Industries Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 12 November 2026).
Is there a Sun Pharma share price forecast for 2026?
What management itself guided: FY27 sales growth high single-digit reiterated. Sun Pharma has reported its July to September 2026 results since this read was written. The earlier read is kept below, closed, until we update it.
What would change the story: Sun Pharma has reported its July to September 2026 results since this read was written. The earlier read is kept below, closed, until we update it.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 12 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.